Literature DB >> 11157595

Vascular endothelial growth factor in human lung transplantation.

K C Meyer1, A L Cardoni, Z Xiang, R D Cornwell, R B Love.   

Abstract

STUDY
OBJECTIVES: To determine levels of the vascular endothelial growth factor (VEGF) isoform consisting of 165 amino acids (VEGF(165)) in BAL fluid (BALF) from lung transplant recipients (LTXs).
DESIGN: Bronchoscopy with BAL was performed on LTXs and normal volunteers (NVs).
SETTING: University hospital. PARTICIPANTS: LTXs (n = 57) and NVs (n = 15). MEASUREMENTS AND RESULT: VEGF(165) concentrations in BALF were higher (mean +/- SEM, 240 +/- 32 pg/mL) for NVs (n = 15) vs 133 +/- 14 pg/mL for LTXs (n = 37) who were stable without evidence of significant rejection or infection at 6 months after transplantation (p < 0.0001). BALF VEGF concentrations sampled at 24 to 48 h, 2 weeks, 4 weeks, and 6 months after transplantation for 11 LTXs who lacked rejection or infection at any time point were 71 +/- 8 pg/mL, 80 +/- 20 pg/mL, 82 +/- 13 pg/mL, and 167 +/- 31 pg/mL, respectively. VEGF concentrations in BALF for LTXs with cytomegalovirus (CMV) pneumonia were 55 +/- 12 pg/mL (n = 10), 117 +/- 33 pg/mL for grade A3 acute rejection (n = 9), and 82 +/- 17 pg/mL (n = 14) for active bronchiolitis obliterans syndrome (BOS). Concentrations of VEGF in BALF at 6 months for the 32 stable recipients with bilateral lung transplantation were significantly higher for those with higher values for FEV(1), and BALF VEGF concentrations were significantly lower in BALF at 6 months for those recipients who subsequently went on to develop BOS (86 +/- 19 pg/mL) vs those who did not (158 +/- 18 pg/mL; p = 0.03). Serum concentrations of VEGF did not correlate with VEGF concentrations in BALF, but serum VEGF was 291 +/- 62 pg/mL at 10 to 14 days after transplantation vs 130 +/- 20 pg/mL at 4 weeks for nine LTXs with paired samples (p < 0.02). Serum VEGF concentrations for NVs (n = 15) were 102 +/- 15 pg/mL vs 94 +/- 17 for stable LTXs (n = 12) at 24 weeks after transplantation and 123 +/- 33 pg/mL for LTXs with active BOS (n = 10).
CONCLUSIONS: BALF VEGF concentrations are particularly depressed at early time points following lung transplantation, gradually improve in the absence of significant rejection or infection, and are lower with active rejection or CMV pneumonia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157595     DOI: 10.1378/chest.119.1.137

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome.

Authors:  Balazs Antus; Imre Barta; Krisztina Czebe; Ildiko Horvath; Eszter Csiszer
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

2.  Human neutrophil peptide in lung chronic allograft dysfunction.

Authors:  Cavan Reilly; Tereza Cervenka; Marshall I Hertz; Trisha Becker; Chris H Wendt
Journal:  Biomarkers       Date:  2011-10-11       Impact factor: 2.658

3.  Role of defensins in the pathogenesis of chronic lung allograft rejection.

Authors:  Venkataswarup Tiriveedhi; Babak Banan; Saini Deepti; Angaswamy Nataraju; Ramsey Hachem; Elbert Trulock; Patterson G Alexander; Mohanakumar Thalachallour
Journal:  Hum Immunol       Date:  2013-12-28       Impact factor: 2.850

4.  Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Brigitte Gomperts; Ying Ying Xue; Kurt Hong; Javier Mestas; Abbas Ardehali; Borna Mehrad; Rajan Saggar; Joseph P Lynch; David J Ross; Robert M Strieter
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury.

Authors:  G D Perkins; J Roberts; D F McAuley; L Armstrong; A Millar; F Gao; D R Thickett
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

6.  De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.

Authors:  Trudie A Goers; Sabarinathan Ramachandran; Aviva Aloush; Elbert Trulock; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 7.  Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome.

Authors:  V E Kennedy; J L Todd; S M Palmer
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

8.  The effect of Nomega-nitro-L-arginine methyl ester and L-arginine on lung injury induced by abdominal aortic occlusion-reperfusion.

Authors:  Huseyin Okutan; Ilker Kiris; Ali K Adiloglu; Cagri Savas; Nilgün Kapucuoğlu; Irfan Altuntas; Onur Akturk
Journal:  Surg Today       Date:  2007-12-24       Impact factor: 2.549

9.  Image-enhanced bronchoscopic evaluation of bronchial mucosal microvasculature in COPD.

Authors:  Eman M Metwally; Hanaa Shafiek; Tamer S Morsi; Bassma El Sabaa; Abdelaziz Elnekidy; Mohamed Elhoffy; Mohamed Samy Atta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-29

10.  Decline in Club Cell Secretory Proteins, Exosomes Induction and Immune Responses to Lung Self-antigens, Kα1 Tubulin and Collagen V, Leading to Chronic Rejection After Human Lung Transplantation.

Authors:  Yoshihiro Itabashi; Ranjithkumar Ravichandran; Sandhya Bansal; Ankit Bharat; Ramsey Hachem; Ross Bremner; Michael Smith; T Mohanakumar
Journal:  Transplantation       Date:  2021-06-01       Impact factor: 5.385

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.